Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 597 Stomach Neoplasms 72 Neoplasm Metastasis 56 Neoplasms 35 HER2-positive Breast Cancer 30 Breast Neoplasms, Male 30 Colorectal Neoplasms 28 Brain Neoplasms 23 Carcinoma, Non-Small-Cell Lung 21 Inflammatory Breast Neoplasms 20 Esophageal Neoplasms 20 Pancreatic Neoplasms 13 Triple Negative Breast Neoplasms 12 Lung Neoplasms 11 Endometrial Neoplasms 11 Ovarian Neoplasms 10 Colonic Neoplasms 10 Urinary Bladder Neoplasms 9 Rectal Neoplasms 9 Prostatic Neoplasms 9 Adenocarcinoma 8 Salivary Gland Neoplasms 7 Gallbladder Neoplasms 7 Breast Diseases 7 Biliary Tract Neoplasms 7 Adenocarcinoma Of Esophagus 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Sarcoma 6 Pathologic Complete Response 6

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × Trastuzumab × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡